What is the recommended treatment regimen for peripheral artery disease?

Peripheral Artery Disease Treatment

All patients with symptomatic PAD must receive aspirin 75-325 mg daily or clopidogrel 75 mg daily as first-line antiplatelet therapy, high-intensity statin therapy regardless of baseline lipids, and supervised exercise training for 30-45 minutes at least 3 times weekly for a minimum of 12 weeks before considering any revascularization. 1, 2

Cardiovascular Risk Reduction (Mandatory for All PAD Patients)

Antiplatelet Therapy

• Aspirin 75-325 mg daily is the first-line antiplatelet agent to reduce myocardial infarction, stroke, and vascular death. 1, 2
• Clopidogrel 75 mg daily is an equally effective alternative to aspirin and may be preferred based on recent evidence. 1, 2, 3
• Dual pathway inhibition with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily should be strongly considered in high-risk patients (especially post-revascularization) who have low bleeding risk. 2
• Dual antiplatelet therapy (aspirin plus clopidogrel) may be considered in symptomatic PAD patients at high cardiovascular risk who are not at increased bleeding risk, though evidence for cardiovascular benefit remains uncertain. 1
• Never add warfarin to antiplatelet therapy—it provides no benefit and significantly increases major bleeding risk. 1, 2

Lipid Management

• High-intensity statin therapy is mandatory for every PAD patient regardless of baseline cholesterol levels, as statins also improve walking distance beyond cardiovascular protection. 1, 2

Blood Pressure Control

• ACE inhibitors or ARBs are the preferred antihypertensive agents because they provide additional ischemic event reduction beyond blood pressure lowering. 2
• Antihypertensive treatment reduces myocardial infarction, stroke, heart failure, and cardiovascular death. 2

Smoking Cessation

• Provide smoking cessation counseling at every visit using behavioral techniques. 2
• Offer pharmacologic aids (varenicline, bupropion, or nicotine replacement) to all current smokers. 2

Diabetes Management

• In PAD patients with diabetes, optimal glycemic control is recommended, with consideration of SGLT2 inhibitors given their cardiovascular benefits. 1, 4

Treatment for Intermittent Claudication

Exercise Therapy (First-Line Treatment)

• Supervised exercise training is the initial therapy and must be attempted before any revascularization. 1, 2
• Program specifications: 30-45 minutes per session, at least 3 sessions per week, continued for a minimum of 12 weeks. 1, 2
• High-intensity walking at 77-95% of maximal heart rate (Borg scale 14-17) yields superior improvements in walking distance compared to lower intensity. 2
• When supervised programs are unavailable, structured home-based programs incorporating behavioral change techniques (accountability to a coach, goal-setting, self-monitoring) are acceptable alternatives. 2, 5
• Unstructured "just walk more" advice is ineffective and should not be recommended. 2

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily is indicated for all patients with lifestyle-limiting claudication who do not have heart failure—it improves symptoms and increases walking distance. 1, 2
• Pentoxifylline 400 mg three times daily may be considered as a second-line alternative to cilostazol, though its clinical effectiveness is marginal and not well established. 1, 2
• Do not prescribe L-arginine, propionyl-L-carnitine, or ginkgo biloba—they have no proven effectiveness for claudication. 1, 2
• Chelation therapy with EDTA is contraindicated due to potential harm. 1, 2

Revascularization Strategy

Indications for Revascularization

• Revascularization is indicated only when claudication remains disabling after an inadequate response to at least 3 months of supervised exercise and optimal medical therapy. 1, 2
• A favorable risk-benefit ratio (e.g., focal aortoiliac disease) further supports proceeding with intervention. 1, 2
• Never perform revascularization in asymptomatic PAD or solely to prevent progression to critical limb-threatening ischemia. 1, 2

Aortoiliac Lesions

• Endovascular therapy is the first-choice strategy for short (<5 cm) aortoiliac occlusive lesions. 1
• Primary stenting is effective for common iliac artery stenosis and occlusions; use provisional stenting in external iliac arteries when balloon angioplasty results in persistent gradient, >50% residual stenosis, or flow-limiting dissection. 1, 2
• Measure translesional pressure gradients (with and without vasodilation) to evaluate iliac stenoses of 50-75% diameter before intervention. 1

Femoropopliteal Lesions

• Endovascular therapy should be the first choice for short (<25 cm) femoropopliteal lesions, even in complex cases, especially for surgical high-risk patients. 1
• Drug-eluting technologies (balloons or stents) are the first-choice endovascular strategy for femoropopliteal lesions. 1, 2
• Open surgical bypass using autologous vein (great saphenous vein) should be considered for long (≥25 cm) superficial femoral artery lesions when the patient has low surgical risk, an available vein, and life expectancy >2 years. 1, 2
• The autologous saphenous vein is the conduit of choice for femoropopliteal bypass. 1
• Do not perform primary stenting in femoral or popliteal arteries—reserve stenting as salvage therapy for failed balloon angioplasty. 2

Below-the-Knee Lesions

• In patients with severe intermittent claudication undergoing femoropopliteal endovascular treatment, below-the-knee arteries may be treated in the same intervention if there is substantially impaired outflow. 1

Post-Revascularization Management

• Continue supervised exercise training as adjunct therapy after endovascular revascularization. 2
• Consider dual pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin) post-revascularization to further reduce cardiovascular and limb events. 1, 2

Critical Limb-Threatening Ischemia (CLTI)

Recognition and Initial Management

• Early recognition of tissue loss and/or infection with immediate referral to a vascular team is mandatory for limb salvage. 1
• Assess risk of amputation using structured tools (e.g., WIfI score). 1, 3
• In diabetic CLTI patients, optimize glycemic control. 1

Revascularization for CLTI

• Revascularization is indicated whenever feasible for limb salvage. 1
• For infrapopliteal revascularization, bypass using the great saphenous vein is the preferred approach. 1
• Do not use stem cell or gene therapy for CLTI—it is not indicated. 1

Acute Limb Ischemia

• In the presence of neurological deficit, urgent revascularization is indicated immediately. 1
• Without neurological deficit, revascularization is indicated within hours after initial imaging based on case-by-case assessment. 1
• Administer heparin and analgesics as soon as possible. 1

Critical Pitfalls to Avoid

• Never proceed to revascularization without first completing at least 3 months of supervised exercise and optimal medical therapy for claudication. 1, 2
• Never perform primary stenting in femoral, popliteal, or tibial arteries except as salvage for failed angioplasty. 2
• Never add warfarin to antiplatelet therapy unless another indication exists—it increases bleeding without cardiovascular benefit. 1, 2
• Never recommend unstructured "just walk more" programs—they are ineffective. 2
• Never withhold cilostazol in eligible claudication patients without heart failure—it has Level A evidence for symptom improvement. 1, 2